Saltar al contenido
Merck
Todas las fotos(3)

Key Documents

View All Documentation

269476

Sigma-Aldrich

N-Acetylprocainamide

≥99%

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(3)

About This Item

Fórmula lineal:
4-(CH3CONH)C6H4CONHCH2CH2N(C2H5)2
Número de CAS:
32795-44-1
Peso molecular:
277.36
MDL number:
MFCD00009052
UNSPSC Code:
12352100
PubChem Substance ID:
24856329
NACRES:
NA.22

Quality Level

200

assay

≥99%

form

solid

mp

138-140 °C (lit.)

solubility

soluble 1%, clear, colorless to faintly yellow (1N HCl)

functional group

amide
amine

SMILES string

CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1

InChI

1S/C15H23N3O2/c1-4-18(5-2)11-10-16-15(20)13-6-8-14(9-7-13)17-12(3)19/h6-9H,4-5,10-11H2,1-3H3,(H,16,20)(H,17,19)

InChI key

KEECCEWTUVWFCV-UHFFFAOYSA-N

General description

The relaxant effects of N-acetylprocainamide on bovine tracheal smooth muscle was studied.

Application

N-acetylprocainamide (NAPA) was used as a model drug in the study of establishing a quantitative approach to predict the renal clearances of basic drugs using N-1-methylnicotinamide (NMN).

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
1328418V
1328418
00704HH
15106LN
07311TX

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Yoo-Seong Jeong et al.
Pharmaceutics, 11(3) (2019-03-09)
Previous observations demonstrated that cimetidine decreased the clearance of procainamide (PA) and/or N-acetylprocainamide (NAPA; the primary metabolite of PA) resulting in the increased systemic exposure and the decrease of urinary excretion. Despite an abundance of in vitro and in vivo
M Boucher et al.
Journal of autonomic pharmacology, 18(2), 83-87 (1998-09-08)
1. The cardiac anticholinergic effects of procainamide (1 mg kg(-1) min(-1)) and its N-acetylated metabolite (NAPA) at equimolar dose (1.16 mg kg(-1) min(-1)) were studied using in vivo experimental pharmacological and in vitro radioligand binding studies. 2. Procainamide and NAPA
Brady S Moffett et al.
Pharmacotherapy, 26(12), 1687-1693 (2006-11-28)
To evaluate dosing and pharmacokinetic parameters of intravenous continuous-infusion procainamide in neonates, and to identify dosage regimens and factors leading to therapeutic procainamide levels and minimal adverse events. Retrospective, observational study. Pediatric hospital. . Twenty-one patients (seven preterm, 14 full
Application of capillary electrophoresis to the in vitro assessment of drug metabolism.
C M Hill et al.
Biochemical Society transactions, 23(3), 432S-432S (1995-08-01)
S D Nelson et al.
The Journal of pharmacology and experimental therapeutics, 273(1), 315-319 (1995-04-01)
Ischemic zone refractoriness and conduction delay respond differently to infarct healing and, hypothetically, may exert discordant influences on the electrophysiologic action of different classes of antiarrhythmic drugs. This study evaluated the influence of infarct healing on the electrophysiologic effects of
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico